Recombinant Human C-C chemokine receptor type 7 (CCR7)

1. Research indicates that CCR7 promotes triple-negative breast cancer (TNBC) metastasis and may serve as a potential target for breast cancer diagnosis and treatment. PMID: 30032244
2. High CCR7 expression has been linked to urinary bladder cancer metastasis. PMID: 28534984
3. Studies suggest that CCL19/CCR7 contributes to the proliferation and invasion of endometrial stromal cells, potentially contributing to endometriosis pathogenesis by activating the PI3K/Akt pathway. PMID: 28856757
4. Research findings demonstrate that the chemokines CCL19, CCL21, and CCR7 play crucial roles in bone destruction by enhancing osteoclast migration and resorption activity. This has been associated with rheumatoid arthritis pathogenesis. PMID: 28729639
5. CXCR4, CCR7, VEGF-C, and VEGF-D expression might have synergistic effects on lymph node metastasis in patients with cervical cancer. PMID: 28535405
6. Patients with acute graft-versus-host disease (aGvHD) received a higher percentage of CD4+CCR7+ T-cells in donor T-cells, while chronic GvHD (cGvHD) patients received a higher percentage of CD8+CCR7+ T-cells. Functional studies indicated that CCR7+ T-cells exhibit a greater potential for activation compared to CCR7- T-cells. PMID: 28112745
7. CCL21/CCR7 interaction has been shown to activate epithelial-mesenchymal transition (EMT) in lung cancer cells via the ERK1/2 signaling pathway. PMID: 28487957
8. The CCL21/CCR7 interaction allows natural killer (NK) cell adhesion to endothelial cells (ECs) and its reduction by hypoxia. PMID: 28416768
9. Research indicates that miR-1275 positively regulates CCR7 expression in squamous cell carcinoma of the head and neck (SCCHN) through different mechanisms. PMID: 29278769
10. Evidence suggests that CCR7 mediates EMT progression via the AKT pathway, highlighting its crucial role in breast cancer progression. PMID: 28378417
11. Studies have reported an increased percentage of peripheral CCR7 T cells accompanied by endothelial dysfunction in patients with ankylosing spondylitis. PMID: 28421995
12. Analysis of gene amplification and mRNA levels suggests that CCR7 expression in breast cancer correlates with better prognosis. PMID: 28930757
13. CCR7 mediates TGF-beta1-induced MMP2/9 expression through NF-kappaB signaling. PMID: 28817313
14. Leukocyte subsets exhibit distinct patterns of CCR7 sialylation, contributing to receptor signaling and fine-tuning chemotactic responses. PMID: 26819318
15. Tumor microenvironment stimulation has been shown to down-regulate the migration of CCR7-expressing tumor cells towards CCL21 and inhibit the formation of directional protrusions towards CCL21 in a novel 3-dimensional hydrogel system. PMID: 26936935
16. CCR7 expression levels in human tumors correlate with signatures of CD141(+) DC, intratumoral T cells, and improved clinical outcomes. PMID: 27424807
17. A specific role for CCL21/CCR7 in promoting EMT and metastasis in CD133+ pancreatic cancer stem-like cells has been identified. PMID: 27505247
18. This study demonstrated that CCR7 is overexpressed in CD4(-) CD8(-) thymocytes of myasthenia gravis patients. PMID: 26616645
19. High tumoral CCR7 expression correlated with potential lymphatic involvement and unfavorable prognosis in metastatic renal cell carcinoma patients undergoing tyrosine kinase inhibitor treatment. PMID: 28114889
20. Results indicate that upregulation of CCR7 promotes cell proliferation and inflammation in A549 non-small cell lung cancer cells. Conversely, silencing of CCR7 via siRNA treatment promotes cell apoptosis and suppresses the inflammatory response and TGF-beta1-induced EMT, potentially linked to NF-kappaB signaling. PMID: 28339080
21. Down-regulating CCR7 expression in MG63 cells significantly inhibits cell proliferation, migration, invasion abilities, and induces cell apoptosis. PMID: 27916085
22. Findings suggest that upregulation of rat CCR7 expression does not alter the phenotype, differentiation, or proliferation capacity of human adipose-derived stem cells (hASCs). However, it enables efficient migration of hASCs to rat secondary lymphoid organs. PMID: 28035134
23. CCL21/CCR7 interaction contributes to the time-dependent proliferation of papillary thyroid carcinoma (PTC) cells by upregulating cyclin A, cyclin B1, and cyclin-dependent kinase 1 (CDK1) expression via the extracellular signal-regulated kinase (ERK) pathway associated with iodine. PMID: 27574129
24. Findings suggest that the CCR7 gene locus harbors a polymorphism that modifies the risk of myocardial infarction in patients with coronary artery disease (CAD). Replication of this association in a prospective cohort of initially healthy individuals could be pursued. PMID: 27317472
25. This study shows that plasmacytoid dendritic cells from rheumatoid arthritis patients have high expression levels of CCR7. PMID: 27421624
26. This study suggests that NRP1 expression and lymphatic vessel density are independent factors that predict the risk of lymph node metastasis in squamous cell carcinoma (SCC) of the tongue. Meanwhile, the expression of VEGFC, VEGFR3, CCR7, and SEMA3E are non-independent predictive factors. PMID: 27666723
27. High CCR7 expression is associated with gastric cancer. PMID: 26984468
28. The CCR7 pathway up-regulates Twist expression via ERK and PI3K/AKT signaling to manage the epithelial-mesenchymal transition process in human pancreatic ductal adenocarcinoma. PMID: 26219899
29. Constitutively expressed Siglec-9 inhibits LPS-induced CCR7 but enhances IL-4-induced CD200R expression in human macrophages. PMID: 26923638
30. High CXCR4 expression in primary breast tumors (PTs) was associated with luminal A type tumor, suggesting a more favorable outcome. In contrast, CCR7 and FOXP3 expressions in PTs represented luminal B tumors, indicating more aggressive tumor behavior. Maspin expression did not differ between luminal types. PMID: 28011488
31. Results indicated that CCR7 is overexpressed in gallbladder cancer tissues, and its expression correlates with staging and lymph node metastasis. PMID: 27009073
32. CCL21/CCR7 induce VEGF-D up-regulation and promote lymphangiogenesis via the ERK/Akt pathway in lung cancer. PMID: 26884842
33. The study demonstrated that down-regulation of CCR7 reduced proliferation, cell cycle progression, cell migration, and invasion in prostate cancer cells. PMID: 26722441
34. Findings suggest that MUC1 plays a significant role in CCL21-CCR7-induced lymphatic metastasis and may serve as a therapeutic target in esophageal squamous cell carcinoma. PMID: 26667143
35. Membrane-associated PGES1-dependent release of PGE2 is accompanied by elevated CCR7 expression in colon cancer cells. PMID: 26352871
36. Pyk2 is a key downstream signaling molecule of CCR7 in SCCHN, promoting SCCHN tumorigenesis and progression. PMID: 26352169
37. The CCR7 axis mediates TGF-beta1-induced EMT via crosstalk with NF-kappaB signaling, facilitating lymph node metastasis and poorer overall survival in patients with gastric cancer. PMID: 26176983
38. Blockade of CCR7 or treatment with a p38 MAP kinase inhibitor reduced lymphatic dissemination of epithelial-mesenchymal transition cells. PMID: 25961925
39. Findings indicated that circulating memory Tfh cells, particularly CCR7+ICOS+ memory Tfh cells, may be associated with multiple sclerosis relapse and could serve as a novel therapeutic target. PMID: 26231034
40. The chemotactic interaction between CCR7 and its ligand, CCL21, might be a critical event during progression in pancreatic cancer. PMID: 21594558
41. CrkL regulates CCL19 and CCR7-induced epithelial-to-mesenchymal transition via the ERK signaling pathway in epithelial ovarian carcinoma patients. PMID: 25636509
42. Recycling accounts, to a significant extent, for the high levels of surface CXCR4/CCR7 on chronic lymphocytic leukemia (CLL) cells. Increased CCR4/CCR7 is detectable not only in circulating leukemic cells but also in secondary lymphoid organs of CLL patients with lymphoadenopathy. PMID: 26282174
43. In given donor/recipient pairs, KIR2DS4 expression may contribute to potentiating natural killer cell function by increasing both cytotoxicity and CCR7 expression on their surface. PMID: 25961063
44. Data indicate that inhibition of TGF-beta-activated protein kinase 1 (TAK1) reduces chemokine (C-C motif) receptor 7 (CCR7) expression. PMID: 25557171
45. The CCL21/CCR7 pathway activates signaling to up-regulate the Slug pathway, leading to the occurrence of epithelial-mesenchymal transition in human chondrosarcoma. PMID: 25556164
46. The study suggests that CCR7 promotes Snail expression to induce the epithelial-mesenchymal transition, resulting in cell cycle progression, migration, and invasion in gastric cancer. PMID: 25572817
47. High CCR7 expression was associated with colorectal cancer metastasis. PMID: 26179425
48. The solution structure of CCL19 has been reported, revealing a canonical chemokine domain. Chemical shift mapping shows that the N-termini of PSGL-1 and CCR7 have overlapping binding sites for CCL19, and binding is competitive. PMID: 26115234
49. These results reveal that CCR7 and VEGF-C exhibit a significant crosstalk and suggest a novel role of the CCL21/CCR7 chemokine axis in promoting breast cancer-induced lymphangiogenesis. PMID: 25744065
50. High expression of CCR-7 is associated with atherosclerotic arteries. PMID: 25318003

Show More

Hide All

HGNC: 1608

OMIM: 600242

KEGG: hsa:1236

STRING: 9606.ENSP00000246657

UniGene: Hs.370036